Will payment based therapy become the mainstream pricing model? Pharmaceutical companies are mixed

Source: Sina pharmaceutical 2017-09-27 photo source: some headlines of Dongfang IC make the mode of payment based on curative effect seem to lead the future pharmaceutical industry, and deal with high drug prices as part of the new medical system But a recent PwC study shows that this pricing model has not been widely accepted from any point of view According to PwC's "launching into value: Pharma's quest to align drug prices with exports" report, only a quarter of the executives of pharmaceutical companies surveyed by PwC Health Research Institute have started to try drug value based agreements Although only a small number of pharmaceutical companies are testing this approach, PwC believes it will have a significant impact on industry information transmission and new policy recommendations Some big pharmaceutical companies, such as Amgen, Sanofi, Novartis and MSD, have signed corresponding value based payment agreements with drug payers Express scripts is ready However, PwC's research shows that this model is still a long way from being widely accepted and adopted From the current situation, 38% of pharmaceutical company leaders believe that the risks brought by this payment method agreement are worthy of bearing from the perspective of benefits According to PwC's survey of 101 executives of pharmaceutical companies and 100 executives of medical insurance companies, 71% of executives of pharmaceutical companies think that this payment method can be used to help patients, and will also put forward new requirements for medical innovation Medical insurance companies, the top five companies in the United States, have signed at least one value based payment agreement Harvard Pilgrim, a smaller insurer, and advocate health care have signed more than one agreement, along with optum Rx One of the advocates of innovative payment agreements and pricing models is Steve Miller, chief medical officer of express scripts, who expressed his strategic intention to challenge the cost of drugs to fierce Pharma in July this year Express scripts has introduced an indication specific pricing strategy for cancer and inflammatory disease treatment drugs, which aims to make the best treatment drugs available for patients' treatment and reduce the number of expensive drugs as much as possible after the launch of similar biological drugs If the patient changes the medication within the specified time, express scripts will be returned with the payment "For patients, if they change their use of anti-inflammatory drugs within 90 days, pharmaceutical companies will return two-thirds of the cost of the drugs," Miller said If a drug costs $3000 a month to use and the patient changes another drug after one month of use, the amount to be returned is $2000 Two months later, the amount of reimbursement was $4000 This fundamentally ensures that patients and doctors can have a wider range of medication " For cancer treatment, if the patient changes the drug within 30 days, the insurance company can get a partial refund "This pricing model is designed to ensure patient outcomes and reduce drug prices, and these agreements will enable pharmaceutical companies and express scripts to work together to achieve these two goals," Miller said According to the research of PWC, although the pricing model based on curative effect has not become the mainstream payment method, the pricing pressure does come from all aspects These pressures force pharmaceutical manufacturers to further justify their drug prices PwC research also suggests that the pricing model currently being tested in the US may help emerging markets develop their own listing strategies.